Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
U73122 is a synthetic small-molecule aza-steroid widely used as a research tool compound and originally characterized as a selective inhibitor of phosphoinositide-specific phospholipase C (PLC), with reported IC50 values around 1–6 µM for PLC-β3 in cell-based systems.[1][2][3][13] It contains an electrophilic maleimide moiety on a 3‑methoxyestradiol core, enabling covalent reaction with cellular nucleophiles and leading to inhibition of PLC-dependent phosphatidylinositol 4,5-bisphosphate hydrolysis, subsequent inositol 1,4,5-trisphosphate and diacylglycerol generation, and downstream Ca2+ and protein kinase C signaling.[1][2][3][6][7][9][13] Subsequent work has shown that U73122 also inhibits phospholipase A2, the sarcoplasmic reticulum Ca2+ pump, and human 5‑lipoxygenase, and exerts diverse effects including antiplatelet activity, inhibition of neutrophil adhesion and degranulation, modulation of Ca2+ homeostasis, and antinociceptive actions, indicating that it is a relatively nonselective covalent modulator of multiple signaling pathways rather than a strictly specific PLC inhibitor.[1][3][4][5][7][9][13]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on U73122.